ImmunityBio (26CA) Financial Statements
ImmunityBio Financial Overview
ImmunityBio's market cap is currently $7.84B. The company's EPS TTM is $-0.97; its P/E ratio is -8.51; ImmunityBio is estimated to report earnings on November 5, 2026, and the estimated EPS forecast is $-0.06. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 113.29M | $ 14.74M | $ 622.00K | $ 240.00K | $ 934.00K |
| Gross Profit | $ 112.53M | $ 14.74M | $ 622.00K | $ 240.00K | $ 934.00K |
| Operating Income | $ -256.03M | $ -344.18M | $ -362.25M | $ -351.30M | $ -330.28M |
| EBITDA | $ -223.56M | $ -264.43M | $ -478.66M | $ -351.88M | $ -320.75M |
| Net Income | $ -351.40M | $ -413.56M | $ -583.20M | $ -416.57M | $ -346.79M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 242.82M | $ 149.81M | $ 266.46M | $ 107.18M | $ 317.12M |
| Total Assets | $ 501.90M | $ 382.93M | $ 504.45M | $ 362.36M | $ 468.91M |
| Total Debt | $ 878.12M | $ 504.17M | $ 726.72M | $ 723.77M | $ 645.66M |
| Net Debt | $ 789.78M | $ 360.74M | $ 461.27M | $ 619.13M | $ 464.56M |
| Total Liabilities | $ 1.00B | $ 871.06M | $ 1.09B | $ 812.18M | $ 712.82M |
| Stockholders' Equity | $ -499.57M | $ -489.10M | $ -586.99M | $ -447.33M | $ -242.17M |
| Cash Flow | |||||
| Free Cash Flow | $ -308.78M | $ -398.12M | $ -397.34M | $ -415.67M | $ -307.98M |
| Operating Cash Flow | $ -304.94M | $ -391.24M | $ -366.76M | $ -337.51M | $ -274.42M |
| Investing Cash Flow | $ -149.80M | $ -12.25M | $ -30.47M | $ 27.30M | $ -84.89M |
| Financing Cash Flow | $ 400.24M | $ 281.63M | $ 558.34M | $ 233.61M | $ 505.44M |
Currency in USD